Notice ID: 4e1a9bafbb524e1eb222f1b9b59da2dfAward NoticeAwarded
Pharmacodynamic and Tolerability studies of candidate AD drugs in a transgenic AD mouse model
Awarded on August 29, 2023. Full description on SAM.gov.
Awarded tounder 75N95023P00617 (source: SAM.gov award notice)• $249.3K
Overview
- Posted
- August 29, 2023
- Notice type
- Award Notice
- NAICS
- 541380: Testing Laboratories and Services
- Agency
- Department of Health and Human Services
Notice details
- Last updated
- Dec 4, 2025
- Award date
- Aug 29, 2023
- Award amount (SAM.gov award notice)
- $249.3K
Identifiers
- Solicitation number
- 75N95023Q00447
- Notice ID
- 4e1a9bafbb524e1eb222f1b9b59da2df
- Award number (PIID)
- 75N95023P00617
Description
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. (ii) The solicitation number is 75N95023Q00447 and the solicitation is issued as a request for quotation (RFQ). This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures; FAR Subpart 13.5— Simplified Procedures for Certain Commercial Items; and FAR Part 12—Acquisition of Commercial Items and is not expected to exceed the simplified acquisition threshold. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) Number 2023-04, with effective date June 2, 2023. (iv) The associated NAICS code 541380 and the small business size standard is $16.5 million. This requirement has no set-aside restrictions. (v) This requirement is for the following services: Pharmacodynamic and Tolerability studies of candidate AD drugs in a transgenic AD mouse model (vi) There is currently a pressing need to identify effective treatments for Alzheimer’s disease (AD). With the repeated failures of multiple pivotal phase-III clinical trials in patients with AD, it is critical to test novel methods of discovering disease-modifying AD treatments. As part of one complete study called the Drug Repurposing for Effective Alzheimer’s Medicines (DREAM) study, one ongoing study called the Experimental Validation of candidate Alzheimer’s disease treatments identified by multi-omics analyses (PREVENT-AD) study, in addition to three ongoing contracts, the NIA IRP is testing the utility of commonly prescribed, FDA-approved drugs that may be repurposed as `candidate AD treatments.’ The proposed acquisition will build on this work to test 1) tolerability of two candidate AD drugs in the 5x-FAD transgenic mouse model of AD to determine their optimal dosing in efficacy studies; and 2) efficacy of two candidate AD drugs in this transgenic AD mouse model. Please see the attached Statement of Work (SOW) for detailed requirements. (vii) The Government anticipates award of a firm fixed-price purchase order for this acquisition, and the anticipated period of performance is: 9/30/2023 – 9/29/2025 (viii) The provision at FAR 52.252-1, Solicitation Provisions Incorporated by Reference (Feb 1998), applies to this acquisition. This solicitation incorporates one or more solicitation provisions by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. The offeror is cautioned that the listed provisions may include blocks that must be completed by the offeror and submitted with its quotation or offer. In lieu of submitting the full text of those provisions, the offeror may identify the provision by paragraph identifier and provide the appropriate information with its quotation or offer. Also, the full text of a solicitation provision may be accessed electronically at these addresses: https://www.acquisition.gov/browse/index/far https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html (End of provision) The following provisions apply to this acquisition and are incorporated by reference: FAR 52.204-7, System for Award Management (OCT 2018) FAR 52.204-16, Commercial and Government Entity Code Reporting (AUG 2020) FAR 52.212-1, Instructions to Offerors-Commercial Items (MAR 2023) FAR 52.212-3, Offeror Representations and Certifications-Commercial Items (DEC 2022) FAR 52.222-22 Previous Contracts and Compliance Reports (FEB 1999) HHSAR 352.239-73, Electronic and Information Technology Accessibility Notice (December 18, 2015) The clause at FAR 52.252-2, Clauses Incorporated by Reference (Feb 1998), applies to this acquisition. This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at these addresses: https://www.acquisition.gov/browse/index/far https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html (End of clause) The following clauses apply to this acquisition and are incorporated by reference: FAR 52.204-13, System for Award Management Maintenance (OCT 2018) FAR 52.204-18, Commercial and Government Entity Code Maintenance (AUG 2020) FAR 52.212-4, Contract Terms and Conditions--Commercial Items (DEC 2022). Addendum to this FAR clause applies to this acquisition and is attached. FAR 52.227-14, Rights in Data – General (MAY 2014) HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (December 18, 2015) HHSAR 352.239-74, Electronic and Information Technology Accessibility (December 18, 2015) The following provisions and clauses apply to this acquisition and are attached in full text. Offerors MUST complete the provisions at 52.204-24 and 52.204-26 and submit completed copies as separate documents with their proposal. FAR 52.204-24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment (NOV 2021) FAR 52.204-26 Covered Telecommunications Equipment or Services-Representation (OCT 2020) FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders--Commercial Items (JUN 2023) The following are also attached, however only one will be incorporated in the final award: Invoicing Instructions With IPP Invoicing Instructions Without IPP (ix) The provision at FAR clause 52.212-2, Evaluation – Commercial Items (NOV 2021), applies to this acquisition. (a) The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered. The following factors shall be used to evaluate offers: (i) technical capability to meet the Government’s requirements; (ii) past performance [see FAR 13.106-2(b)(3)]; (iii) price. Technical and past performance, when combined, are significantly more important than price. (b) A written notice of award or acceptance of an offer, mailed or otherwise furnished to the successful offeror within the time for acceptance specified in the offer, shall result in a binding contract without further action by either party. Before the offer’s specified expiration time, the Government may accept an offer (or part of an offer), whether or not there are negotiations after its receipt, unless a written notice of withdrawal is received before award. (x) The Offerors to include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications-Commercial Items (DEC 2022), with its offer. If the offeror has completed FAR clause 52.212-3 at www.sam.gov, then the offeror does not need to provide a completed copy with its offer. (xi) The clause at FAR 52.212-4, Contract Terms and Conditions-Commercial Items (DEC 2022), applies to this acquisition. Addendum to this FAR clause applies to this acquisition and is attached. (xii) There are no additional contract requirement(s) or terms and conditions applicable to this acquisition. (xiii) The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. (xiv) Responses to this solicitation must include clear and convincing evidence of the offeror’s capability of fulfilling the requirement as it relates to the technical evaluation criteria. The price proposal must include the labor categories, an estimate of the number of hours required for each labor category, fully loaded fixed hourly rate or each labor category, breakdown and rationale for other direct costs or materials, and the total amount. The Unique Entity ID from SAM.gov, the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. All questions must be received by 12:00 pm Eastern Time, on Friday, July 28, 2023, and reference Solicitation Number 75N95023Q00447. Questions may be submitted electronically to Rashiid.Cummins@nih.gov All quotations must be received by 12:00 pm Eastern Time, on Monday, August 21, 2023, and reference Solicitation Number 75N95023Q00447. Responses must be submitted electronically to Rashiid.Cummins@nih.gov. Fax responses will not be accepted.
Award Overview
Award Number
75N95023P00617
Award Amount (SAM.gov award notice)
$249.3K
Award Date
Aug 29, 2023
Awardee
Awardee UEI
ED41XCPBEPU1
Original Solicitation
Notice ID: 4e1a9bafbb524e1eb222f1b9b59da2df
Posted Date: Aug 29, 2023
Original Response Deadline: Not specified
More From This Vendor
Top 5 most recent
- $249.0KSigned May 2, 2025
- $249.0KSigned Dec 6, 2024
Contacts
Documents
No documents available.
Lifecycle
Solicitation:
75N95023Q00447- Market Research
- Combined Synopsis
- Awarded
This opportunity has been awarded.
- Market ResearchJul 3, 2023
SOURCES SOUGHT: Pharmacodynamic and Tolerability studies of candidate AD drugs in a transgenic AD mouse model
- Combined SynopsisJul 21, 2023
Pharmacodynamic and Tolerability studies of candidate AD drugs in a transgenic AD mouse model
- AwardedCurrentAug 29, 2023
Pharmacodynamic and Tolerability studies of candidate AD drugs in a transgenic AD mouse model
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
THIS IS A SOURCES SOUGHT ANNOUNCEMENT ONLY. It is neither a solicitation announcement nor a request for proposals or quotes and does not obligate the Government to award a contract. Requests for a solicitation will not receive a response. Responses to this sources sought must be in writing. The purpose of this sources sought announcement is for market research to make appropriate acquisition decisions and to gain knowledge of potential qualified Small Businesses interested and capable of providing the services described below. NIH-OD-SS-27-000058 The information gained from this market research will help the National Institutes (NIH) Clinical Center (CC) plan for its acquisition strategy. Potential Large and Small Businesses shall include business information outlined in the section below as a part of their response. Complete responses to this notice shall be in the following format: SAM UEI Number and CAGE code Company Name Company Address, City, State and Zip Code Company Point of Contact, Email Address and Telephone Number Current GSA Schedule appropriate to this Sources Sought of other FAR Part 8 considerations Socioeconomic Status: (i.e., HUBZone, 8a, Small Business, Women Owned Small Business, Veteran-Owned Small-Business, etc.) https://www.sam.gov. Provide a capability statement that addresses the organizations qualifications and ability to perform as a contractor for the work described in the Statement of Work. The NIH Clinical Center Office of Research Support and Compliance (ORSC) is seeking a qualified and experienced contractor to provide project management and coordination of routine and emergent qualification, calibration/PM and certification services, including repairs and replacements, for the departments/ICs located at the NIH’s Bethesda, MD campus. Please see attached SOW for more details. Contractors shall not reach out to the customer for any questions or clarifications. All communications must go through contracting. ****************************************************************************** Important information: The Government is not obligated to nor will it pay for or reimburse any costs associated with responding to this source sought synopsis request. This notice shall not be construed as a commitment by the Government to issue a solicitation or ultimately award a contract, nor does it restrict the Government to a particular acquisition approach. The Government will in no way be bound to this information if any solicitation is issued. No sub-contracting opportunity is anticipated. NAICS: The North American Classification System (NAICS) code for this acquisition is 541380. PSC: H966 Notice to potential offerors: All offerors who provide goods or services to the United States Federal Government must be registered and have an active registration in the System for Award Management (SAM) at www.sam.gov and complete Online Representations and Certifications Application (ORCA). All interested Offerors should submit information by e-mail to ryssa.nix@nih.gov. Please use subject line “Response to NIH-OD-SS-27-000058”. All information submissions shall be received no later than noon on November 15, 2026. | - | Pre-Solicitation | 11/15/2026 |
INTRODUCTION THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institutes of Health (NIH) intends to negotiate and award a contract without providing for full and open competition (Including brand-name) to: Alcami Corporation 2320 Scientific Park DR Wilmington, North Carolina 28405-1800 NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE The intended procurement is classified under NAICS code 541380 with a Size Standard $16.6M. REGULATORY AUTHORITY The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2026-01, March 13, 2026. This acquisition is conducted under the procedures as prescribed in FAR subpart 13-Simplified Acquisition Procedures at an amount not exceeding the simplified acquisition threshold ($350,000). STATUTORY AUTHORITY This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures, Subpart 13.106-1 (b) (1), Soliciting from a single source and is not expected to exceed the simplified acquisition threshold. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements. GENERAL INFORMATION Title: Stability Testing for ManNAc Drug Product produced in Campaigns 5 and 6. Stability testing will occur under regulatory compliance Background Information: NHGRI was gifted 48kg of unlabeled drug ManNAc (powder-in-sachet) in September 2025, and agreed to take over the FDA-required, mandatory, stability testing program of this drug that has been ongoing at Alcami Corporation since June 2024. The gifted drug was produced in 2 campaigns, Campaign 5 (C5, June 2024) and Campaign 6 (C6, September 2024). NHGRI plans to use the donated clinical grade drug for upcoming clinical trials. CLOSING STATEMENT This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include a technical proposal, a cost-price proposal, the period of performance, the Unique Entity ID (UEI), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by November 9, 2026 at 9:00 AM Eastern time and must reference solicitation number 75N98027Q00040. Responses may be submitted electronically to Mr. James Law, Contracting Officer at James.Law@nih.gov. Fax responses will not be accepted. "All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency.” | - | Pre-Solicitation | 11/09/2026 |
Centers for Disease Control (CDC) is issuing this synopsis as a means of conducting market research to identify parties having an interest in and the resources to support this requirement for a California-based integrated health care system to serve as an electronic health record site in CDC’s VISION 2.0 respiratory pathogen surveillance network, providing integrated, longitudinal medical, laboratory, pharmacy, vaccination, claims, and outcomes data to support influenza surveillance, vaccine-effectiveness studies, and related respiratory pathogen research across emergency/urgent care, inpatient, and intensive care unit (ICU) settings. The result of this market research will contribute to determining the method of acquisition. The applicable North American Industry Classification System (NAICS) code assigned to this acquisition is 541380- Testing Laboratories and Services. | - | Market Research | 12/04/2026 |
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued. (ii) The solicitation number is 75N98026Q01209/PCA-NIA-08501. This solicitation is issued as a Notice of Intent (NOI) for a non-competitive combined synopsis/solicitation to award a contract or purchase order without providing for full and open competition (including brand-name, if applicable). This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii). The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a firm fix-price award on a non-competitive basis to Epigenetic Clock Development Foundation 1124 W. Carson Street, MRL Bldg., 3rd Floor Torrance, CA 90502 US to provide obtain DNA methylation profiling and epigenetic age analysis for 320 previously extracted murine DNA samples using the Mammal320K methylation array and established Horvath epigenetic clock methodologies. | - | Combined Synopsis | 09/23/2026 |
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued. (ii) The solicitation number is 75N98026Q01212/PCA-NIA-08124. This solicitation is issued as a Notice of Intent (NOI) for a non-competitive combined synopsis/solicitation to award a contract or purchase order without providing for full and open competition (including brand-name, if applicable). This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii). The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a firm fix-price award on a non-competitive basis to Metabolon Inc. 617 Davis Drive, Suite 100, Morrisville, NC 27560 to assay global metabolomics data and short chain fatty acids (SCFA) via the Metabolon platform from 369 blood samples in the BLSA. These metabolomics data will be used to identify metabolomic signatures of anthropometric aging quantified via a 3D body scanner. | - | Combined Synopsis | 09/23/2026 |
Additional Details
Solicitation Number
75N95023Q00447
Archive Date
Sep 13, 2023
Place of Performance Country
AUT
Office Address
Bethesda, MD, 20892